Schrödinger, Inc. (NASDAQ:SDGR) Insider Margaret Dugan Sells 1,531 Shares of Stock

Schrödinger, Inc. (NASDAQ:SDGR) insider Margaret Dugan sold 1,531 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total value of $27,221.18. Following the completion of the sale, the insider now owns 13,469 shares of the company’s stock, valued at approximately $239,478.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Schrödinger Trading Up 1.5 %

SDGR stock opened at $17.92 on Thursday. The stock has a market cap of $1.30 billion, a P/E ratio of -6.69 and a beta of 1.50. The stock’s fifty day simple moving average is $19.36 and its two-hundred day simple moving average is $21.39. Schrödinger, Inc. has a 1-year low of $16.67 and a 1-year high of $38.00.

Schrödinger (NASDAQ:SDGR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.11. Schrödinger had a negative net margin of 100.42% and a negative return on equity of 38.38%. The company had revenue of $47.33 million during the quarter, compared to analyst estimates of $40.19 million. As a group, analysts forecast that Schrödinger, Inc. will post -2.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Leerink Partners assumed coverage on shares of Schrödinger in a research report on Tuesday, July 2nd. They set an “outperform” rating and a $29.00 price objective for the company. Morgan Stanley lowered their price target on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 21st. KeyCorp reduced their price objective on Schrödinger from $30.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Leerink Partnrs raised Schrödinger to a “strong-buy” rating in a research note on Tuesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.44.

Hedge Funds Weigh In On Schrödinger

Several hedge funds have recently made changes to their positions in SDGR. Nisa Investment Advisors LLC boosted its stake in Schrödinger by 145.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock valued at $27,000 after buying an additional 837 shares during the period. GAMMA Investing LLC boosted its position in shares of Schrödinger by 49.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after acquiring an additional 703 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Schrödinger during the 2nd quarter valued at about $66,000. PNC Financial Services Group Inc. grew its holdings in shares of Schrödinger by 186.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,127 shares of the company’s stock worth $76,000 after purchasing an additional 1,385 shares in the last quarter. Finally, Quest Partners LLC increased its position in shares of Schrödinger by 1,005.6% in the second quarter. Quest Partners LLC now owns 4,555 shares of the company’s stock worth $88,000 after purchasing an additional 4,143 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.